PhageTech Revenue and Competitors

PhageTech, Inc. is a California-based, developmental stage company applying an innovative approach for detecting disease markers in body fluids including urine and blood. Compared to current antibody-based assays, PhageTech's approach could offer improved sensitivity and performance. Furthermore, our technology has the potential to be more stable and less expensive than current testing methods. The PhageTech, Inc. technology platform promises to deliver rapid and accurate diagnostic screening for testing at a fraction of current costs. The core technology utilized in PhageTech devices was developed by two research groups at the University of California, Irvine, and was the subject of nine pending and issued patents. Recently, protein sensing with the PhageTech platform has been demonstrated with PSMA (Prostate-specific membrane antigen) and HSA (Human Serum Albumin). These targets could impact the diagnosis of prostate cancer and kidney disease, respectively. Our technology has the potential to touch every field of medicine and profoundly impact the administration of health care around the world.